Analyst Roanna Ruiz from Leerink Partners maintained a Hold rating on Amarin (AMRN – Research Report) and increased the price target to $9.00 from $1.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Roanna Ruiz’s rating is based on a combination of factors influencing Amarin’s current market position. The recent 1-for-20 ADS ratio change has improved Amarin’s compliance with NASDAQ, effectively reducing the share count and contributing to an increased price target of $9. Additionally, there is a noticeable rise in European revenues for Vazkepa, attributed to enhanced market access and growing adoption in countries with established pricing and reimbursement frameworks.
Despite these positive developments, Roanna maintains a Hold rating due to persistent challenges in the US market, where Vascepa faces significant competition from generic alternatives. While there is potential for growth if European revenues continue to increase, the current market dynamics in the US present a cautious outlook, prompting a neutral stance until more substantial evidence of revenue inflection is observed.
According to TipRanks, Ruiz is an analyst with an average return of -14.6% and a 28.76% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Cormedix, Cytokinetics, and Lantheus.